Table 2 Baseline use of psychotropic medications across samples of the three published randomized controlled trials of DBT-A for suicidal and self-harming adolescents with borderline features
From: Psychotropic medication use among adolescents participating in three randomized trials of DBT
Drug class | US sample | Oslo sample | Barcelona sample | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
All participants (N = 173) | Participants with MD (n = 142; 82.1%) | All participants (N = 77) | Participants with MD (n = 17; 22.1%) | All participants (N = 35) | Participants with MD (n = 29; 82.9%) | |||||||||
n | % | n | % | N | % | n | % | n | % | n | % | |||
Any medication with psychiatric use | 116 | 67.1 | 92 | 64.8 | 9 | 11.7 | 6 | 35.3 | 30 | 85.7 | 25 | 86.2 | ||
Antidepressant (any) | 104 | 60.1 | 82 | 57.7 | 5 | 6.5 | 2 | 11.8 | 23 | 65.7 | 21 | 72.4 | ||
SSRI | 90 | 52.0 | 71 | 50.0 | 4 | 5.2 | 1 | 5.9 | 19 | 54.3 | - | - | ||
SNRI | 8 | 4.6 | 6 | 4.2 | 0 | 0 | 0 | 0 | 2 | 5.7 | - | - | ||
Tricyclic | 1 | 0.6 | 1 | 0.7 | 0 | 0 | 0 | 0 | 1 | 2.8 | - | - | ||
Other | 22 | 12.7 | 18 | 12.7 | 1 | 1.3 | 1 | 5.9 | 1 | 2.8 | - | - | ||
Anxiolytic (any) | 13 | 7.5 | 12 | 8.5 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 17.2 | ||
Benzodiazepine | 10 | 5.8 | 10 | 7.0 | 0 | 0 | 0 | 0 | 5 | 14.3 | - | - | ||
Antipsychotic | 38 | 22.0 | 30 | 21.1 | 1 | 1.3 | 1 | 5.9 | 26 | 74.2 | 21 | 72.4 | ||
Mood stabilizer a | 28 | 16.2 | 24 | 16.9 | 0 | 0 | 0 | 0 | 5 | 14.2 | 4 | 13.8 | ||
CNS Stimulant | 17 | 9.8 | 13 | 9.2 | 1 | 1.3 | 1 | 5.9 | 5 | 14.2 | 5 | 17.2 | ||
Alpha adrenergic | 5 | 2.9 | 4 | 2.8 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||
Antihistamine | 8 | 4.6 | 8 | 5.6 | 2 | 2.6 | 2 | 11.8 | 0 | 0 | - | - | ||
Other b | 3 | 1.7 | 2 | 1.4 | 1 | 1.3 | 0 | 0 | 1 | 2.8 | 1 | 3.4 | ||
Total number of medications (mean, SD) | 1.44 | 1.51 | 1.44 | 1.56 | 0.13 | 0.38 | 0.16 | 0.36 | 1.8 | 1.13 | - | - | ||